<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03986762</url>
  </required_header>
  <id_info>
    <org_study_id>25506</org_study_id>
    <nct_id>NCT03986762</nct_id>
  </id_info>
  <brief_title>Open Label Pharmaco- Magnetic Resonance Spectrography (MRS) Study of Clavulanic Acid</brief_title>
  <acronym>CLAVMRPilot</acronym>
  <official_title>A Phase IA Open Label Pharmaco- Magnetic Resonance Spectrography (MRS) Study of Clavulanic Acid Daily Repeated Administration in Remitted Cocaine Use Disorder Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Temple University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Temple University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to determine how the study drug, clavulanic acid, affects
      glutamate in the brain using Magnetic Resonance (MR/MRI) scans. In this study, subjects will
      receive the study drug, clavulanic acid and undergo 4 MRI scans. This is being studied to
      determine the correct dosing of clavulanic acid, and to gather data so future studies can be
      done to find out if this drug is helpful in treating cocaine dependence. Currently, there is
      no available medication treatment for cocaine dependence.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 12, 2019</start_date>
  <completion_date type="Actual">December 20, 2019</completion_date>
  <primary_completion_date type="Actual">December 20, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glutamate change from baseline</measure>
    <time_frame>10-17 Days</time_frame>
    <description>Change in brain glutamate concentration at Day 10-17 compared with baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glutamate/creatine ratio change from baseline</measure>
    <time_frame>10-17 Days</time_frame>
    <description>Change in brain glutamate/creatine ratio at Day 10-17</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glutamate change after dose stoppage</measure>
    <time_frame>Day 10-11</time_frame>
    <description>Change in brain glutamate concentration in 2 brain areas associated with addiction at Day 11 compared with Day 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glutamate/creatine ratio change after dose stoppage</measure>
    <time_frame>Day 10-11</time_frame>
    <description>Change in brain glutamate/creatine ratio in 2 brain areas associated with addiction at Day 11 compared with Day 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in brain glutamine from baseline</measure>
    <time_frame>10-17 Days</time_frame>
    <description>Change in brain glutamine concentration in 2 brain areas at Day 10-17 compared with baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in brain glutamine/creatine ratio from baseline</measure>
    <time_frame>10-17 Days</time_frame>
    <description>Change in glutamine/creatine ratio in 2 brain areas at Day 10-17 compared with baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events (AEs) as assessed by comprehensive metabolic panel, complete blood count, ekg, urinalysis, C-SSRS, and any self-reported change in health.</measure>
    <time_frame>1-31 days (during and after study dosing period)</time_frame>
    <description>Adverse events (AES) will be defined as any clinically significant changes in vital signs, indications of suicidal ideation or behavior on the Columbia Suicide Severity Rating Scale (C-SSRS), clinically significant change in Electrocardiogram (EKG) parameters and clinically significant changes in laboratory bloodwork (Complete blood count, comprehensive metabolic panel, urinalysis), or any self reported side effects compared with baseline.
AEs will be collected throughout the study and reviewed by a physician. An evaluation of AE severity (mild, moderate, severe) will be evaluated by a physician based on participant self-report. AEs per subject will be listed by organ system, and the number of AEs within the subject population will be totaled.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Cocaine Dependence, in Remission</condition>
  <condition>Cocaine Abuse, in Remission</condition>
  <condition>Cocaine-Related Disorders</condition>
  <arm_group>
    <arm_group_label>Open Label Clav</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clavulanic Acid</intervention_name>
    <description>~10 days of Clavulanic Acid</description>
    <arm_group_label>Open Label Clav</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meet DSM-5 criteria for cocaine use disorder, moderate to severe in early remission.

          -  Be male or female adult volunteers ages 18-65 inclusive.

          -  If female and of childbearing potential, must have a negative pregnancy test within 48
             hours of beginning the study and be willing to use acceptable contraception or be
             abstinent for 14 days prior to study, through the entire study and 30 days after study
             participation.

        Exclusion Criteria:

          -  Be unable to complete an MRI scan

        (For full inclusion/exclusion criteria or for more information, please contact the site
        directly.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary F Morrison, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Temple University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Episcopal Hospital Medical Arts Building</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Uys JD, LaLumiere RT. Glutamate: the new frontier in pharmacotherapy for cocaine addiction. CNS Neurol Disord Drug Targets. 2008 Nov;7(5):482-91. Review.</citation>
    <PMID>19128205</PMID>
  </reference>
  <reference>
    <citation>Rasmussen BA, Baron DA, Kim JK, Unterwald EM, Rawls SM. β-Lactam antibiotic produces a sustained reduction in extracellular glutamate in the nucleus accumbens of rats. Amino Acids. 2011 Feb;40(2):761-4. doi: 10.1007/s00726-010-0589-0. Epub 2010 Apr 13.</citation>
    <PMID>20383795</PMID>
  </reference>
  <reference>
    <citation>Ward SJ, Rasmussen BA, Corley G, Henry C, Kim JK, Walker EA, Rawls SM. Beta-lactam antibiotic decreases acquisition of and motivation to respond for cocaine, but not sweet food, in C57Bl/6 mice. Behav Pharmacol. 2011 Aug;22(4):370-3. doi: 10.1097/FBP.0b013e3283473c10.</citation>
    <PMID>21543969</PMID>
  </reference>
  <reference>
    <citation>Kovalevich J, Corley G, Yen W, Rawls SM, Langford D. Cocaine-induced loss of white matter proteins in the adult mouse nucleus accumbens is attenuated by administration of a β-lactam antibiotic during cocaine withdrawal. Am J Pathol. 2012 Dec;181(6):1921-7. doi: 10.1016/j.ajpath.2012.08.013. Epub 2012 Sep 29.</citation>
    <PMID>23031254</PMID>
  </reference>
  <reference>
    <citation>Ramadan S, Lin A, Stanwell P. Glutamate and glutamine: a review of in vivo MRS in the human brain. NMR Biomed. 2013 Dec;26(12):1630-46. doi: 10.1002/nbm.3045. Epub 2013 Oct 4. Review.</citation>
    <PMID>24123328</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>February 15, 2019</study_first_submitted>
  <study_first_submitted_qc>June 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2019</study_first_posted>
  <last_update_submitted>June 22, 2020</last_update_submitted>
  <last_update_submitted_qc>June 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clavulanic Acids</mesh_term>
    <mesh_term>Clavulanic Acid</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 24, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/62/NCT03986762/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

